Sugi Predict

Sugi Predict / Targets / KCNAB1

KCNAB1

Voltage-gated potassium channel subunit beta-1 · Q14722 · KCNAB1 on Sugi Atlas →

1,307 patent compounds predicted against KCNAB1, 836 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1945000 SCHEMBL1945000 1.00 10/20
SCHEMBL1945019 SCHEMBL1945019 1.00 10/20
SCHEMBL1945507 SCHEMBL1945507 1.00 10/20
SCHEMBL1945846 SCHEMBL1945846 1.00 10/20
SCHEMBL1946003 SCHEMBL1946003 1.00 10/20
SCHEMBL1946008 SCHEMBL1946008 1.00 10/20
SCHEMBL1947206 SCHEMBL1947206 1.00 10/20
SCHEMBL1947591 SCHEMBL1947591 1.00 10/20
SCHEMBL1948073 SCHEMBL1948073 1.00 10/20
SCHEMBL1945005 SCHEMBL1945005 0.92 10/20
SCHEMBL1945192 SCHEMBL1945192 0.92 10/20
SCHEMBL1944493 SCHEMBL1944493 0.92 10/20
SCHEMBL1949184 SCHEMBL1949184 0.88 10/20
SCHEMBL1945844 SCHEMBL1945844 0.86 10/20
SCHEMBL1946654 SCHEMBL1946654 0.84 10/20
SCHEMBL1946194 SCHEMBL1946194 0.84 10/20
SCHEMBL1946349 SCHEMBL1946349 0.83 10/20
SCHEMBL1945902 SCHEMBL1945902 0.82 10/20
SCHEMBL1947342 SCHEMBL1947342 0.82 10/20
SCHEMBL1944620 SCHEMBL1944620 0.80 10/20

Clinical trials — most relevant to KCNAB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery PHASE4RECRUITING
Multimodal Versus Opioid aNalgesia in carDiAc Surgery PHASE4COMPLETED
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease PHASE4NOT_YET_RECRUITING
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study PHASE3COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy PHASE1/PHASE2RECRUITING
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy PHASE2RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss PHASE2COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats nanCOMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies nanUNKNOWN
Gene Study for Infantile Onset Diabetes nanUNKNOWN
Characteristics of Episodic Ataxia Syndrome nanCOMPLETED
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
Cenobamate Expanded Access Program (EAP) nanAPPROVED_FOR_MARKETING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KCNAB1 binder may also engage these)

ProteinNameSimilarity
Q9XT31 — 1.000 Q9XT31 →
P63143 — 1.000 P63143 →
Q9PWR1 — 0.999 Q9PWR1 →
Q4PJK1 — 0.998 Q4PJK1 →
P63144 — 0.997 P63144 →
Q28528 — 0.997 Q28528 →
Q9PTM5 — 0.972 Q9PTM5 →
P62483 — 0.965 P62483 →
P62482 — 0.964 P62482 →
Q13303 — 0.962 Q13303 →
Q27955 — 0.960 Q27955 →
A0A2R8QFQ6 — 0.942 A0A2R8QFQ6 →
G3MWR8 — 0.940 G3MWR8 →
Q8CJ19 — 0.940 Q8CJ19 →
D3Z7P3 — 0.939 D3Z7P3 →
Q7RTP6 — 0.938 Q7RTP6 →
Q4W5Z4 — 0.936 Q4W5Z4 →
Q6DD70 — 0.935 Q6DD70 →
Q2HJ19 — 0.935 Q2HJ19 →
P13264 — 0.935 P13264 →
GLS Glutaminase kidney isoform, mitochondrial 0.935 landscape →
Q1LZ53 — 0.934 Q1LZ53 →
Q3ULA2 — 0.934 Q3ULA2 →
Q5XIJ5 — 0.931 Q5XIJ5 →
Q6GL10 — 0.931 Q6GL10 →
O88508 — 0.931 O88508 →
Q99JW1 — 0.931 Q99JW1 →
Q9Y297 — 0.930 Q9Y297 →
DHX9 ATP-dependent RNA helicase A 0.930 landscape →
Q28141 — 0.929 Q28141 →